Most Recent Articles about LGND
https://www.zacks.com/stock/news/2260461/corcept-cort-posts-positive-data-from-cushing-s-syndrome-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260461
Apr 23, 2024 - Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
zc:4431029445523520777
0
https://www.zacks.com/stock/news/2260438/sanofi-sny-rilzabrutinib-shows-benefit-in-blood-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260438
Apr 23, 2024 - Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
zc:180300507628057938
0
https://www.zacks.com/stock/news/2259547/will-alkermes-alks-proprietary-drugs-aid-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2259547
Apr 22, 2024 - Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
zc:-3447874097353586196
0